---
category: news
title: "BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in Japan"
excerpt: "BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab (Brand Name in the"
publishedDateTime: 2023-01-16T01:55:00Z
originalUrl: "https://www.benzinga.com/pressreleases/23/01/n30424948/bioarctics-partner-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-fo"
webUrl: "https://www.benzinga.com/pressreleases/23/01/n30424948/bioarctics-partner-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-fo"
type: article
quality: 4
heat: 4
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - Computer Vision
  - AI
  - AI in Marketing

secured: "E8IA3dfPDHXSKFqEQQ8veFM+RBYEASnzLk3WYWKqypTeyvkdJACIIqOuGtyLoGzSw+VBf2OxmO3kiNWiyZZHhRjCCGesM/RSsuSxjuxF+iM2U/JQIWTgGsNfbOa8uw8EvIuwUj0pf7GLA7Us/kMRlFtQ7Y5TWxmMzM4UHKW4VU/i/FwmIopbv8OPxaAFyaCks4K5TeDEipmeOnyp7TlrqU37gMAEPbDRL3lFAg4nwrXkj740fifA8BYHpRzO535CARWsVTALXGOXhkIfnig593eCjoO/sKutJes+GeksVp630a6FxbEZAuBmJCzzloezl1vmhhgAhMMJB+jpLw9oUU8uLGcdxzSJWrdVbvKzFMk=;qQwlKm4hhuvm2etjEDAKuQ=="
---

